Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739480 | 0.89 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1308625 | 0.86 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL190405 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL190642 | 0.81 | PIK3CA (0.70) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL188671 | 0.81 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL189697 | 0.81 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL960078 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL29439930 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL189616 | 0.80 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1310187 | 0.80 | PIK3CA (0.44) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | claimed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | claimed |
| CN-101479274-B | Pharmaceutical compounds | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | claimed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | claimed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | claimed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 3/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 4/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.